SCHEMBL5657364

SCHEMBL5657364

O=C(O)C1CCN(CCc2ccc3oc(=O)[nH]c3c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.49
SLC6A2 P23975 3/20 0.49
SLC6A3 Q01959 3/20 0.49
S1PR1 P21453 2/20 0.46
S1PR3 Q99500 2/20 0.46
KCNH2 Q12809 2/20 0.45
MCHR2 Q969V1 1/20 0.45
MCHR1 Q99705 1/20 0.45
GRIN1 Q05586 3/20 0.45
GRIN2D O15399 2/20 0.45
GRIN3B O60391 2/20 0.45
GRIN2A Q12879 2/20 0.45
GRIN2B Q13224 2/20 0.45
GRIN2C Q14957 2/20 0.45
GRIN3A Q8TCU5 2/20 0.45
SLC6A4 P31645 1/20 0.43
LTA4H P09960 2/20 0.43
HTR2A P28223 3/20 0.43
HTR7 P34969 2/20 0.43
DRD2 P14416 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6664492 0.80 KCNH2 (0.41) HTR1ASLC6A2SLC6A3S1PR1S1PR3
SCHEMBL5655532 0.75 HTR1A (0.56) HTR1ASLC6A2SLC6A3S1PR1S1PR3
SCHEMBL8100829 0.74 DRD2 (0.53) HTR1ASLC6A2SLC6A3GRIN1GRIN2D
SCHEMBL8109896 0.73 GRIN1 (0.69) HTR1AGRIN1GRIN2DGRIN3BGRIN2A
SCHEMBL8947955 0.73 HTR2A (0.55) HTR1ASLC6A2SLC6A3KCNH2GRIN1
SCHEMBL14573151 0.73 KCNH2 (0.47) KCNH2
SCHEMBL5656040 0.72 MEN1 (0.53)
SCHEMBL5657151 0.72 SLC6A4 (0.50) HTR1AKCNH2SLC6A4LTA4HHTR2A
SCHEMBL5657894 0.72 POLB (0.56) HTR1ASLC6A2SLC6A3KCNH2MCHR2
SCHEMBL1519356 0.72 HTR2A (0.75) LTA4HHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392686-B1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2006-10-18 EP claimed
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-10-07 US claimed
US-7186730-B2 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2007-03-06 US disclosed
EP-1392686-B1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2006-10-18 EP disclosed
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-10-07 US disclosed
EP-1392686-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-03 EP disclosed
WO-2002096907-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials NRDC, NUCB2, ASNS HTR1A 3274/4885SLC6A2 3187/4885SLC6A3 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.